Insider Buying: Zura Bio (NASDAQ:ZURA) Major Shareholder Purchases 2,000,000 Shares of Stock

Zura Bio Limited (NASDAQ:ZURA) major shareholder Ai Biotechnology Llc acquired 2,000,000 shares of the business’s stock in a transaction on Thursday, February 26th. The stock was acquired at an average price of $6.25 per share, with a total value of $12,500,000.00. Following the transaction, the insider directly owned 6,552,725 shares of the company’s stock, valued at $40,954,531.25. This represents a 43.93% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Zura Bio Stock Up 2.1%

Shares of NASDAQ ZURA traded up $0.14 during midday trading on Monday, hitting $6.76. The company had a trading volume of 421,166 shares, compared to its average volume of 727,424. The firm has a market capitalization of $439.56 million, a price-to-earnings ratio of -10.40 and a beta of 0.21. Zura Bio Limited has a twelve month low of $0.97 and a twelve month high of $7.19. The business has a 50-day simple moving average of $5.68 and a two-hundred day simple moving average of $4.08.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. Allworth Financial LP purchased a new stake in Zura Bio during the fourth quarter worth approximately $30,000. Savant Capital LLC raised its stake in shares of Zura Bio by 190.4% in the 2nd quarter. Savant Capital LLC now owns 32,409 shares of the company’s stock valued at $34,000 after acquiring an additional 21,249 shares during the period. Scientech Research LLC acquired a new position in shares of Zura Bio during the 3rd quarter valued at $45,000. AQR Capital Management LLC purchased a new stake in Zura Bio during the 1st quarter worth $72,000. Finally, Forefront Wealth Partners LLC acquired a new stake in Zura Bio in the 3rd quarter valued at $93,000. 61.14% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ZURA has been the subject of a number of research reports. Wall Street Zen cut shares of Zura Bio from a “hold” rating to a “sell” rating in a research report on Sunday, November 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zura Bio in a research note on Friday, January 9th. Leerink Partners upgraded Zura Bio to a “strong-buy” rating in a report on Sunday, November 23rd. Wedbush started coverage on Zura Bio in a research report on Monday, February 9th. They set an “outperform” rating and a $15.00 price target for the company. Finally, Chardan Capital reissued a “buy” rating and issued a $10.00 price target on shares of Zura Bio in a report on Friday, November 14th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Zura Bio currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.60.

Zura Bio Company Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.